Wedbush Increases MacroGenics (NASDAQ:MGNX) Price Target to $16.00

Share on StockTwits

MacroGenics (NASDAQ:MGNX) had its price target raised by investment analysts at Wedbush from $14.00 to $16.00 in a research report issued on Tuesday, BenzingaRatingsTable reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 42.10% from the stock’s current price.

MGNX has been the subject of a number of other reports. Citigroup dropped their price target on shares of MacroGenics from $39.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Zacks Investment Research upgraded shares of MacroGenics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Thursday, January 9th. BidaskClub upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a research report on Friday, December 20th. BTIG Research reiterated a “positive” rating and issued a $23.00 price target on shares of MacroGenics in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald began coverage on shares of MacroGenics in a research report on Wednesday, December 18th. They issued an “overweight” rating and a $17.00 price target for the company. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. MacroGenics has an average rating of “Buy” and an average target price of $22.98.

Shares of NASDAQ MGNX opened at $11.26 on Tuesday. The firm has a 50 day moving average of $10.66 and a 200 day moving average of $12.02. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $551.27 million, a price-to-earnings ratio of -3.12 and a beta of 2.31. MacroGenics has a 12-month low of $7.43 and a 12-month high of $32.32.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.94) by $0.03. The business had revenue of $18.74 million during the quarter, compared to analyst estimates of $23.33 million. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. Sell-side analysts predict that MacroGenics will post -3.4 EPS for the current year.

Several large investors have recently modified their holdings of the stock. Marshall Wace North America L.P. purchased a new stake in MacroGenics during the first quarter valued at $59,000. Marshall Wace LLP purchased a new position in MacroGenics in the 1st quarter worth about $80,000. Tower Research Capital LLC TRC purchased a new position in MacroGenics in the 3rd quarter worth about $94,000. Alpine Global Management LLC purchased a new position in MacroGenics in the 4th quarter worth about $135,000. Finally, Metropolitan Life Insurance Co NY increased its stake in MacroGenics by 23.4% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 16,259 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 3,081 shares during the period. Hedge funds and other institutional investors own 94.92% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

See Also: Profit Margin

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hasbro, Inc.  Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Hasbro, Inc. Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Halozyme Therapeutics, Inc.  to Post Q1 2020 Earnings of  Per Share, Piper Sandler Forecasts
Halozyme Therapeutics, Inc. to Post Q1 2020 Earnings of Per Share, Piper Sandler Forecasts
Q1 2020 EPS Estimates for Helios Technologies  Boosted by William Blair
Q1 2020 EPS Estimates for Helios Technologies Boosted by William Blair
Aergo Price Down 15.4% This Week
Aergo Price Down 15.4% This Week
Skychain  Market Capitalization Achieves $662,118.00
Skychain Market Capitalization Achieves $662,118.00
EveriToken  Trading Down 27.4% Over Last Week
EveriToken Trading Down 27.4% Over Last Week


 
© 2006-2020 Zolmax.